Literature DB >> 2953508

Free and Apo B-associated Lpa-specific protein in human serum.

A Gries, J Nimpf, M Nimpf, H Wurm, G M Kostner.   

Abstract

The distribution of Lpa-specific protein (Apo A) among various fractions of human serum was investigated. The following results were obtained. In very low density lipoproteins (VLDL) of fasting human serum Apo A cannot be detected. Most of Apo A is complexed to LDL forming lipoprotein a (Lpa) present in the density fraction of 1.006-1.125 g/ml. Only approximately 5% of Apo A are found in the d greater than 1.125 bottom fraction after ultracentrifugation. Phosphotungstate-Mg (PTA), heparin-Mn (Hep) and dextran sulfate-Mg (DS) precipitate approximately 95% of serum Lpa together with the Apo B containing lipoproteins. Also monospecific antibodies against Apo B do not precipitate all Lpa and leave approximately 3% of Apo A in the supernatant. With polyethylene glycol (PEG) on the other hand, virtually all Lpa is removed since this reagent also precipitates Lpa and Apo A. Apo A of the bottom fraction after ultracentrifugation and of the supernatant after selective precipitation is not stainable with Sudan black and probably represents a protein which is not associated with lipids.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2953508     DOI: 10.1016/0009-8981(87)90110-0

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  8 in total

1.  Distribution of apolipoprotein(a) in the plasma from patients with lipoprotein lipase deficiency and with type III hyperlipoproteinemia. No evidence for a triglyceride-rich precursor of lipoprotein(a).

Authors:  C Sandholzer; G Feussner; J Brunzell; G Utermann
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

Review 2.  Lipoprotein (a): a historical appraisal.

Authors:  Karam M Kostner; Gert M Kostner
Journal:  J Lipid Res       Date:  2016-11-07       Impact factor: 5.922

3.  Linkage between the loci for the Lp(a) lipoprotein (LP) and plasminogen (PLG).

Authors:  L R Weitkamp; S A Guttormsen; J S Schultz
Journal:  Hum Genet       Date:  1988-05       Impact factor: 4.132

Review 4.  Lp(a) and the Risk for Cardiovascular Disease: Focus on the Lp(a) Paradox in Diabetes Mellitus.

Authors:  Karam M Kostner; Gerhard M Kostner
Journal:  Int J Mol Sci       Date:  2022-03-25       Impact factor: 5.923

5.  Genome-Wide Characterization of a Highly Penetrant Form of Hyperlipoprotein(a)emia Associated With Genetically Elevated Cardiovascular Risk.

Authors:  Stefan Coassin; Kevin Chemello; Ilya Khantalin; Lukas Forer; Patricia Döttelmayer; Sebastian Schönherr; Rebecca Grüneis; Clément Chong-Hong-Fong; Brice Nativel; Stéphane Ramin-Mangata; Antonio Gallo; Mathias Roche; Beatrix Muelegger; Christian Gieger; Annette Peters; Johannes Zschocke; Catherine Marimoutou; Olivier Meilhac; Claudia Lamina; Florian Kronenberg; Valentin Blanchard; Gilles Lambert
Journal:  Circ Genom Precis Med       Date:  2022-02-08

Review 6.  The metabolism of lipoprotein (a): an ever-evolving story.

Authors:  Gissette Reyes-Soffer; Henry N Ginsberg; Rajasekhar Ramakrishnan
Journal:  J Lipid Res       Date:  2017-07-18       Impact factor: 5.922

7.  Investigating the Atherogenic Risk of Lipoprotein(a) in Type 2 Diabetic Patients.

Authors:  Jagannadha R Peela; Omar B Latiwesh; Farag Elshaari; Azhar Hussain; Elsa Tabrez; Emily Viglianco; Ajené Edwards; Farwa Ali; Avinash K Rawal
Journal:  Cureus       Date:  2018-07-23

Review 8.  Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule.

Authors:  Motasim M Jawi; Jiri Frohlich; Sammy Y Chan
Journal:  J Lipids       Date:  2020-02-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.